Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (2766)	6/10/1998 8:48:00 PM
From: Bill Wexler	Read Replies (1) \| Respond to of 5736

Oh darn. Guess who's going to appear on CNN tomorrow... NEW YORK, June 10 /PRNewswire/ -- Manuel P. Asensio of Asensio & Company, Inc. is scheduled to appear on the CNN/FN cable channel tomorrow, June 11, 1998 at 9:10 AM on the program "Before Hours." Mr. Asensio is scheduled to be interviewed by Mr. John Metaxas concerning Asensio & Company's Chromatics Color Sciences International, Inc. (OTC Bulletin Board: CCSI) research report. It is also expected that the topics will include Chromatics' dissemination of material false information to investors concerning the uniqueness and sales potential of its non-invasive bilirubinometer product and Dreyfus' trading in Chromatics' stock. Asensio & Company's Strong Sell recommendation estimates the value of Chromatics' stock to be less than $1 per share. Asensio & Company is a New York based institutional investment bank specializing in corporate valuations and equity research. Asensio & Company also specializes in investigating fraudulent stock promotions and publishing research on grossly overvalued companies. Asensio & Company's published research reports, including a copy of our report on Chromatics Color Sciences International, Inc. and a complete record of our previous Strong Sell reports, are available on Asensio & Company's internet home page located at asensio.com. SOURCE Asensio & Company, Inc.

To: JanyBlueEyes who wrote (2766)	6/10/1998 9:06:00 PM
From: Quad Sevens	Respond to of 5736

From Asensio: "In fact, CCSI's FDA approval is based on the fact that the Colormate III is "substantially equivalent" to other existing colorimeters, including one that has been on the market for well over forty years." The FDA approval was based on nothing of the kind. The FDA compared Colormate III with two (note: only two) other devices. They said: " The Colormate III is "substantially equivalent" (as defined in 21 U.S.C. S 360c(i)) in principle, performance, and safety and effectiveness to at least two legally marketed predicate devices. The first predicate device, the Unistat Bilirubinometer manufactured by Leica, Inc.(K922770), is a bilirubinometer which operates by measuring the absorption of visible light through a sample of unreacted serum. The absorption at several wavelengths determines the level of bilirubin present in the sample. The second device, the Ingram Icterometer, commercially distributed preenactment (marketed since 1950's) by Cascade Health Care Products, Salem, Oregon, is a noninvasive aid used as a color reference by the physician during his/her visual assessment of the newborn's skin for jaundice or yellowing. The yellow color of the subcutaneous tissue is matched to a corresponding "yellow hue" stripe for a reference score." The first device is a bilirubinometer that REQUIRES A BLOOD SAMPLE. The second "device" is the one Asensio excitedly reports "has been on the market for well over forty years". (It was on the market "preenactment", i.e., before the FDA issued verdicts on such mechanical devices). It's noninvasive all right. It doesn't do anything as far as I can see. It DEPENDS ON VISUAL ASSESSMENT BY THE PHYSICIAN. The FDA: "The painted stripes of precisely graded yellow hues in the Ingram Icterometer provide the physician with a visual aid to gauge the depth of jaundice in the newborns and estimate the serum bilirubin levels." It sounds like the second device is nothing more than a bunch of closely graded painted stripes, with some implied bilirubin levels along side each, which the tired eyes of the physician tries to compare to the newborn's skin, LOL. The FDA's term "substantially equivalent" does not mean "roughly the same" in the usual sense. It has a technical meaning. Many products given FDA approval as "substantially equivalent" to existing products are clearly superior to the referenced products. It is obvious from the FDA report that Colormate III differs substantially from both of the referenced products. The FDA said nothing about other devices. Wade